June 02, 2016

Bayer Pharma AG v. Watson Laboratories, Inc.

Track this case

Case Number:

16-2169

Court:

Appellate - Federal Circuit

Nature of Suit:

830 Patent Infringement (Fed. Question)

Companies

Sectors & Industries:

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. November 01, 2017

    Fed. Circ. Axes Bayer ED Drug Patent, Reversing Lower Court

    The Federal Circuit ruled Wednesday that a Bayer patent on the erectile dysfunction drug Staxyn is invalid as obvious, handing a win to generics maker Teva with a strongly worded finding that a Delaware federal judge "clearly erred" when he found that the patent was not invalid.


Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!